Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention

by Gansevoort, R.T., Correa-Rotter, R., Hemmelgarn, B.R., Jafar, T.H., Heerspink, H.J.L., Mann, J.F., Matsushita, K., Wen, C.P.
Published 2016

Development and Validation of a General Population Renal Risk Score

by Halbesma, N., Jansen, D.F., Heymans, M.W., Stolk, R.P., Jong, P.E. de, Gansevoort, R.T., PREVEND Study Grp
Published 2011

Proteomics of Urinary Vesicles Links Plakins and Complement to Polycystic Kidney Disease

by Salih, M., Demmers, J.A., Berstarosti, K., Leonhard, W.N., Losekoot, M., Kooten, C. van, Gansevoort, R.T., Peters, D.J.M., Zietse, R., Hoorn, E.J., DIPAK Consortium
Published 2016

Stability of creatinine and cystatin C in whole blood

by Spithoven, E.M., Bakker, S.J.L., Kootstra-Ros, J.E., Jong, P.E. de, Gansevoort, R.T., DIPAK Consortium Investigators
Published 2013

Changes in renal risk factors versus renal function outcome during follow-up in a population-based cohort study

by Halbesma, N., Jansen, D.F., Stolk, R.P., Jong, P.E. de, Gansevoort, R.T., PREVEND Study Grp
Published 2010

A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease

by Casteleijn, N.F., Visser, F.W., Drenth, J.P.H., Gevers, T.J.G., Groen, G.J., Hogan, M.C., Gansevoort, R.T., DIPAK Consortium
Published 2014

Low Urinary Creatinine Excretion Is Associated With Self-Reported Frailty in Patients With Advanced Chronic Kidney Disease

by Polinder-Bos, H.A., Nacak, H., Dekker, F.W., Bakker, S.J.L., Gaillard, C.A.J.M., Gansevoort, R.T.
Published 2017

Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease

by Boertien, W.E., Meijer, E., Zittema, D., Dijk, M.A. van, Rabelink, T.J., Breuning, M.H., Struck, J., Bakker, S.J.L., Peters, D.J.M., Jong, P.E. de, Gansevoort, R.T.
Published 2012

Polycystic kidney disease caused by bilineal inheritance of truncating PKD1 as well as PKD2 mutations

by Losekoot, M., Meijer, E., Hagen, E.C., Belostotsky, V., Borst, M. de, Tholens, A., Phylipsen, M., Pei, Y., Gansevoort, R.T., Peters, D.J.M.
Published 2020

Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model

by Leonhard, W.N., Wal, A. van der, Novalic, Z., Kunnen, S.J., Gansevoort, R.T., Breuning, M.H., Heer, E. de, Peters, D.J.M.
Published 2011

Lower body mass index and mortality in older adults starting dialysis (vol 8, 12858, 2018)

by Polinder-Bos, H.A., Diepen, M. van, Dekker, F.W., Hoogeveen, E.K., Franssen, C.F.M., Gansevoort, R.T., Gaillard, C.A.J.M.
Published 2018

Novel treatment protocol for ameliorating refractory, chronic pain in patients with autosomal dominant polycystic kidney disease

by Casteleijn, N.F., Gastel, M.D.A. van, Blankestijn, P.J., Drenth, J.P.H., Jager, R.L. de, Leliveld, A.M., Stellema, R., Wolff, A.P., Groen, G.J., Gansevoort, R.T., DIPAK Consortium
Published 2017

Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug

by Meijer, E., Gansevoort, R.T., Jong, P.E. de, Wal, A.M. van der, Leonhard, W.N., Krey, S.R. de, Born, J. van den, Mulder, G.M., Goor, H. van, Struck, J., Heer, E. de, Peters, D.J.M.
Published 2011

Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease

by Zittema, D., Versteeg, I.B., Gansevoort, R.T., Goor, H. van, Heer, E. de, Veraar, K.A.M., Peters, D.J.M., Meijer, E.
Published 2016

Association of Mild to Moderate Chronic Kidney Disease With Venous Thromboembolism Pooled Analysis of Five Prospective General Population Cohorts

by Mahmoodi, B.K., Gansevoort, R.T., Naess, I.A., Lutsey, P.L., Braekkan, S.K., Veeger, N.J.G.M., Brodin, E.E., Meijer, K., Sang, Y.Y., Matsushita, K., Hallan, S.I., Hammerstrom, J., Cannegieter, S.C., Astor, B.C., Coresh, J., Folsom, A.R., Hansen, J.B., Cushman, M.
Published 2012

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care

by Harris, T., Sandford, R., Coninck, B. de, Devuyst, O., Drenth, J.P.H., Ecder, T., Kent, A., Gansevoort, R.T., Gorriz, J.L., Ong, A.C.M., Pirson, Y., Torres, V.E., Budde, K., Clement, D., Derchi, L.E., Eleftheroudi, M., Levtchenko, E., Peters, D., Poppel, H. van, Vanholder, R.
Published 2018

Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicente...

by Lantinga, M.A., D'Agnolo, H.M.A., Casteleijn, N.F., Fijter, J.W. de, Meijer, E., Messchendorp, A.L., Peters, D.J.M., Salih, M., Spithoven, E.M., Soonawala, D., Visser, F.W., Wetzels, J.F.M., Zietse, R., Drenth, J.P.H., Gansevoort, R.T., DIPAK Consortium
Published 2017

Detecting PKD1 variants in polycystic kidney disease patients by single-molecule long-read sequencing

by Borras, D.M., Vossen, R.H.A.M., Liem, M., Buermans, H.P.J., Dauwerse, H., Heusden, D. van, Gansevoort, R.T., Dunnen, J.T. den, Janssen, B., Peters, D.J.M., Losekoot, M., Anvar, S.Y.
Published 2017

Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression

by Messchendorp, A.L., Meijer, E., Boertien, W.E., Engels, G.E., Casteleijn, N.F., Spithoven, E.M., Losekoot, M., Burgerhof, J.G.M., Peters, D.J.M., Gansevoort, R.T., DIPAK Consortium
Published 2018

The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease

by D'Agnolo, H.M.A., Casteleijn, N.F., Gevers, T.J.G., Fijter, H. de, Gastel, M.D.A. van, Messchendorp, A.L., Peters, D.J.M., Salih, M., Soonawala, D., Spithoven, E.M., Visser, F.W., Wetzels, J.F.M., Zietse, R., Gansevoort, R.T., Drenth, J.P.H.
Published 2017